Comparing of Melinta Therapeutics Inc. (MLNT) and Zafgen Inc. (NASDAQ:ZFGN)

Melinta Therapeutics Inc. (NASDAQ:MLNT) and Zafgen Inc. (NASDAQ:ZFGN), are influenced by compare since they are both players in the Biotechnology. These factors are particularly influence the profitability, analyst recommendations, risk, dividends, institutional ownership, earnings and valuation of the two firms.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Melinta Therapeutics Inc. 3 0.00 10.29M -15.68 0.00
Zafgen Inc. 1 0.00 25.83M -1.73 0.00

In table 1 we can see Melinta Therapeutics Inc. and Zafgen Inc.’s top-line revenue, earnings per share (EPS) and valuation.


Table 2 hightlights the return on equity, net margins and return on assets of the two companies.

Net Margins Return on Equity Return on Assets
Melinta Therapeutics Inc. 392,403,615.15% -71.6% -32.3%
Zafgen Inc. 3,381,775,333.86% -70.6% -52.8%

Volatility and Risk

Melinta Therapeutics Inc.’s 4.21 beta indicates that its volatility is 321.00% more volatile than that of Standard and Poor’s 500. Competitively, Zafgen Inc. is 148.00% less volatile than Standard and Poor’s 500, because of the -0.48 beta.


The Current Ratio and a Quick Ratio of Melinta Therapeutics Inc. are 1.4 and 1.1. Competitively, Zafgen Inc. has 7.8 and 7.8 for Current and Quick Ratio. Zafgen Inc.’s better ability to pay short and long-term obligations than Melinta Therapeutics Inc.

Analyst Ratings

Melinta Therapeutics Inc. and Zafgen Inc. Ratings and Recommendations are available in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Melinta Therapeutics Inc. 0 0 0 0.00
Zafgen Inc. 0 1 0 2.00

On the other hand, Zafgen Inc.’s potential downside is -3.82% and its average price target is $0.78.

Insider and Institutional Ownership

The shares of both Melinta Therapeutics Inc. and Zafgen Inc. are owned by institutional investors at 24.3% and 81.8% respectively. Melinta Therapeutics Inc.’s share held by insiders are 0.3%. On the other hand, insiders held about 1.14% of Zafgen Inc.’s shares.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Melinta Therapeutics Inc. -1.73% -43.69% -5.92% -4.34% -84.58% 0.16%
Zafgen Inc. -13.33% -22.22% -64.45% -78.89% -91.17% -81.62%

For the past year Melinta Therapeutics Inc. had bullish trend while Zafgen Inc. had bearish trend.


Zafgen Inc. beats Melinta Therapeutics Inc. on 7 of the 10 factors.

Melinta Therapeutics, Inc., an antibiotics company, is engaged in the discovery, development, and commercialization of antibiotics to overcome drug-resistant, life-threatening infections. It develops Delafloxacin, a fluoroquinolone for acute bacterial skin and skin structure infections caused by Gram-positive and Gram-negative bacteria; and Baxdela for the treatment of patients with acute bacterial skin and skin structure infections. Melinta Therapeutics, Inc. was formerly known as formerly Rib-X Pharmaceuticals and changed its name to Melinta Therapeutics, Inc. on October 7, 2013. The company was founded in 2000 and is headquartered in New Haven, Connecticut with an additional office in Lincolnshire, Illinois.

Zafgen, Inc., a biopharmaceutical company, focuses on the development of therapeutics for patients suffering from metabolic diseases comprising type 2 diabetes and obesity. The companyÂ’s lead product candidate is ZGN-1061, a fumagillin-class MetAP2 inhibitor administered by subcutaneous injection, which is in Phase 1 clinical trial and profiled for its utility in the treatment of metabolic diseases. Zafgen, Inc. was founded in 2005 and is based in Boston, Massachusetts.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.